Immune dysregulation disease with immunodeficiency associated with EBV susceptibility

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Oct 1989

Lutrepulse: FDA approved

For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

Lutrepulse

Ferring Laboratories, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Lutrepulse

(Gonadorelin acetate)Orphan drug

Ferring Laboratories, Inc.

Approved Oct 1989

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Immune dysregulation disease with immunodeficiency associated with EBV susceptibility.
Search all trials →
Search clinical trials for Immune dysregulation disease with immunodeficiency associated with EBV susceptibility

Recent News & Research

No recent news articles indexed yet for Immune dysregulation disease with immunodeficiency associated with EBV susceptibility.
Search PubMed for Immune dysregulation disease with immunodeficiency associated with EBV susceptibility

Browse all Immune dysregulation disease with immunodeficiency associated with EBV susceptibility news →

Specialist Network

No specialists currently listed for Immune dysregulation disease with immunodeficiency associated with EBV susceptibility.

View all Immune dysregulation disease with immunodeficiency associated with EBV susceptibility specialists →

Quick Actions